What do you mean my new scale is ‘designed for GLP-1 users’?

These are Optimizerweekly newspaper sent from Edge chief inspector Victoria Song that dissects and discusses new gizmos and potions that swear they will change your life. Choose Optimizer Here.

A few days ago, I walked into the basement of a downtown gym. Sweet and savory food was served. Fresh from the gym, sweaty fitness promoters (and other sweaty journalists) sat around on leather sofas and couches. We were all there to get our hands on the genius level. But not only each one smart scale. We were there for Withings BodyFitA smart scale marketed as “designed for GLP-1 users.”

That didn’t happen because, for all intents and purposes, the $280 BodyFit scale is a budget, standard-fit version of Withings’ more premium $500 Body Scan scale. As it is, it has a retractable handle that enables the analysis of body parts through bioimpedance technology, but leaves a familiar clinical appearance. I have detailed the pros and cons of smart scales in my review of another Withings scalebut cultural intelligence scales, according to how bioimpedance technology works, in general just measure your lower body and use the algorithm to increase your total body mass. Your body shape includes your upper body and torso by including additional dimensions.

So how does this relate to GLP-1 users? Thinly. GLP-1 medications such as Ozempic, Wegovy, Zepbound, and Mounjaro slow down your digestive system and reduce appetite. A possible result of this is that many users end up losing muscle. That’s why doctors recommend that GLP-1 users prioritize a protein diet and exercise regularly. Withings’ statement here is that body weight can help you manage your muscles. That he can be useful! But it’s easy to say that the current technology was designed specifically for GLP-1 users.

“GLP-1 therapy has revolutionized obesity care, but it has not eliminated the need for long-term treatment,” says Antoine Pivron, Withings’ vice president of healthcare. “Drugs help, but sustainable results come from combining support and care with continuous health information. What we’re seeing is a shift toward personalized and metabolically-focused care, and that’s where Withings has been focusing for years.”

When I checked my database for information about Withings’s GLP-1 products for BodyFit, Pivron was right! I have been many times records of increase consideration for metabolic data in protected areas. And he was given that about one in eight Americans have taken or are taking GLP-1 drugs, we are about to see more GLP-1 commercials from the health industry. His story, last week Oura announced, too Setting up the interface to provide “GLP-1 information” in his app.

Like Dr. Doofenshmirtz meme goes: If I had a nickel every time in the last 10 days a major health technology company announced GLP-1 technology, I’d have two nickels. It’s not much, but it and surprisingly it happened twice.

I am aware of the GLP-1 commercials – not as a health reporter, but as someone who currently has GLP-1 drugs to treat him. metabolic syndrome. The frequency of GLP-1 activity is high, but mine has not always been pleasant. For the past six months, I’ve been experiencing every possible problem that can occur in the sun, including an incredibly long-lasting flare-up despite taking the lowest possible dose. It has changed, in many ways, my life. Desperate to feel better again, my instinct was to try to use the medical technology available to diagnose, monitor, and optimize my treatment.

It’s been a rough ride.

It’s one thing to review medical technology when you’re feeling better and better. It’s something else where you are continuously no. I could say 2,000 words about how wearables and AI health products work together. In other words, most of the “facts” and features are designed for “common” use. Good if you are; disappointing if not. Individual technology should address this, but it is a situation that, for now, it does not fully correspond to the current situation. For example: Cutting down trees and its consequences? Boring, but easy with a lot of technology. Understanding how this relates to other metrics and identifying patterns so you can have a better conversation with your doctor? Well, I hope you enjoy spending hours crunching numbers, training AI health educators, checking every piece of information, printing charts, and explaining to doctors why it’s important in the 15 to 30 minutes you’re given. I have the benefit of being paid to do this. Many people who seek guidance, organizations, and support do not.

Intellectually, I understand why the health industry sees the popularity of GLP-1 drugs as an opportunity for innovation. Withings isn’t bad at saying, hey, a smart scale can be a useful tool if you’re concerned about GLP-1-related muscle loss. I wish Oura’s GLP-1 component was available for me to try when I first started taking one. It is designed to help you keep track of your dosages and track your symptoms. It also uses AI insights to let you know if what you’re experiencing is normal at the time you’re there or if you need to see a doctor. For example, let’s say you notice your resting heart rate starts to creep up after you start taking medication. GLP-1s can cause thisbut since it is not dangerous, you are told not to worry. On paper, I see it as a useful setup. I’m curious to see how it fares in short term testing.

Now that I have a BodyFit scale to try, and a few body part measurements under my belt, I have a lot of questions! The original data from the BodyFit Scale says I have the same muscle mass for my age and gender! It really, it higher above average for several parts of my body, but somehow, in total, not enough. I also have a lot of body fat – but it all seems to be very low (seemingly toxic but not too dangerous) as my visceral fat reading is very low! Is this the correct interpretation? If so, should I just hit the body fat goal my doctor set and call it a day? What should I do if I have short-term fatigue? If not, how do I know which issue is the most important to check my limited bandwidth? What does all this mean for my situation?!

Or this is all normal and, once again, I am unknowingly falling into the familiar trap of health data fatigue.

The problem with calling BodyFit a GLP-1 tool is that its scope here is too broad. You can lose muscle mass for a number of reasons. Maybe it’s medicine. Maybe it’s because you’ve been through some life events and haven’t been able to connect with studies for a few months. I could ask the Withings AI bot, but that would mean spending time teaching other AI health chats with my experience. A task that I find tedious, boring, and often with no guarantee of a useful story.

Personally, I believe both Withings and Oura have good intentions with this GLP-1 product. But from the user’s point of view, the problem is maintenance. Based on my experience – what I realize is unmatched each one GLP-1 users – Oura goal is very interesting because it solves a real problem that I have and need help with. It is a popular tool with clear actions that I can choose to use or ignore. In the future, it may be used for other drugs that are often used as a way to help people between visits to the doctor.

The Withings design has its advantages. Me too, according to my doctor InBody Scalethey have lost muscle. It would be good, luckily, to focus on my protein intake and monitor my body’s metabolism at home so I don’t lose weight. But I did already they’ve been doing this with a different Withings scale. So the real “benefit” I get, as a GLP-1 user, is the detailed monitoring of my body composition.

In any case, I wouldn’t be surprised if by this time next year, GLP-1 users will have access to more technological tools. Here’s hoping at least others make navigating support Less difficulties.